Management of Acute Sinus Infection
Diagnosis: Distinguishing Viral from Bacterial Sinusitis
Most acute sinus infections are viral and resolve spontaneously within 7–10 days without antibiotics; prescribe antibiotics only when bacterial infection is confirmed by specific clinical patterns. 1
Approximately 98–99.5% of acute rhinosinusitis cases are viral and do not require antibiotic therapy. 1, 2
Diagnose acute bacterial rhinosinusitis (ABRS) when ANY ONE of the following three patterns is present:
- Persistent symptoms ≥10 days without improvement: purulent nasal discharge plus either nasal obstruction/congestion OR facial pain/pressure/fullness. 1, 2, 3
- Severe symptoms ≥3–4 consecutive days at illness onset: high fever (≥39°C/102.2°F) AND purulent nasal discharge AND facial pain. 1, 2, 3
- "Double sickening": initial improvement from a viral upper respiratory infection followed by new or worsening symptoms (fever, headache, increased nasal discharge) within 10 days. 1, 2, 3
Do NOT prescribe antibiotics for symptoms lasting <10 days unless the severe pattern (high fever ≥39°C with purulent discharge for ≥3 consecutive days) is present. 1, 2
Nasal discharge color alone does not indicate bacterial infection; viral infections naturally progress from clear to purulent discharge over several days due to neutrophil influx. 2, 3
First-Line Antibiotic Therapy for Confirmed Bacterial Sinusitis
Amoxicillin-clavulanate 875 mg/125 mg orally twice daily for 5–10 days is the preferred first-line regimen for otherwise healthy adults with confirmed ABRS, providing 90–92% predicted clinical efficacy against the major pathogens. 1
Standard adult dose: 875 mg/125 mg twice daily for most patients. 1
High-dose regimen (2 g/125 mg twice daily) is indicated when any of the following risk factors are present: recent antibiotic use (within past 4–6 weeks), age >65 years, daycare exposure, moderate-to-severe symptoms, comorbidities (diabetes, chronic cardiac/hepatic/renal disease), or immunocompromised state. 1
Treatment duration: 5–10 days or until symptom-free for 7 consecutive days (typically 10–14 days total). Recent evidence supports shorter 5–7 day courses as equally effective with fewer adverse effects. 1
Plain amoxicillin (500 mg twice daily for mild disease or 875 mg twice daily for moderate disease) may be used only in patients with mild symptoms who have not received antibiotics in the previous 4–6 weeks. 1
Alternatives for Penicillin Allergy
Non-Severe (Non-Type I) Penicillin Allergy
- Second- or third-generation cephalosporins (e.g., cefuroxime-axetil, cefpodoxime-proxetil, cefdinir, cefprozil) for 10 days are appropriate; cross-reactivity with penicillins is negligible (<1%). 1
Severe (Type I/Anaphylactic) Penicillin Allergy
Respiratory fluoroquinolones are the preferred first-line agents:
- Levofloxacin 500 mg once daily for 10–14 days OR
- Moxifloxacin 400 mg once daily for 10 days
- Both achieve 90–92% predicted efficacy against multidrug-resistant Streptococcus pneumoniae and β-lactamase-producing organisms. 1
Doxycycline 100 mg once daily for 10 days is an acceptable but suboptimal alternative (predicted efficacy 77–81% with a 20–25% bacteriologic failure rate) due to limited activity against Haemophilus influenzae. 1
Watchful Waiting (Observation Without Immediate Antibiotics)
For uncomplicated ABRS with reliable follow-up, initial observation without antibiotics is appropriate; initiate antibiotics only if there is no improvement by day 7 or if symptoms worsen at any time. 1, 4
- The number needed to treat (NNT) with antibiotics is 10–15 to achieve one additional cure compared with placebo, reflecting the high spontaneous recovery rate. 1
Essential Adjunctive Therapies (Add to All Patients)
Intranasal corticosteroids (e.g., mometasone, fluticasone, budesonide) administered twice daily significantly reduce mucosal inflammation and accelerate symptom resolution; supported by strong evidence from multiple randomized controlled trials. 1, 2
Saline nasal irrigation performed 2–3 times daily provides symptomatic relief and aids mucus clearance. 1, 2
Analgesics (acetaminophen or ibuprofen) for pain and fever control. 1, 2
Monitoring, Reassessment, and Treatment Failure
Reassess at 3–5 days of antibiotic therapy: if there is no clinical improvement (persistent purulent drainage, unchanged facial pain, or worsening), switch to high-dose amoxicillin-clavulanate (2 g/125 mg twice daily) or a respiratory fluoroquinolone (levofloxacin or moxifloxacin). 1, 2
Reassess at 7 days: persistent or worsening symptoms require (1) confirmation of ABRS diagnosis, (2) exclusion of complications (e.g., orbital cellulitis, meningitis, intracranial abscess), (3) imaging (CT) only if complications are suspected, and (4) referral to ENT when appropriate. 1, 4
Expected timeline of recovery: Noticeable improvement should occur within 3–5 days of appropriate therapy, with complete resolution by 10–14 days or when symptom-free for 7 consecutive days. 1
Antibiotics to Avoid in ABRS
Macrolides (azithromycin, clarithromycin): 20–25% resistance rates in S. pneumoniae and H. influenzae make them unsuitable. 1
Trimethoprim-sulfamethoxazole: ≈50% resistance in S. pneumoniae and ≈27% in H. influenzae. 1
First-generation cephalosporins (e.g., cephalexin): inadequate coverage since ≈50% of H. influenzae strains produce β-lactamase. 1
Referral to Otolaryngology
Refer immediately for any of the following:
- No improvement after 7 days of appropriate second-line antibiotic therapy. 1
- Worsening symptoms at any point during treatment. 1
- Suspected complications: severe headache, visual changes, periorbital swelling/erythema, proptosis, diplopia, altered mental status, or cranial nerve deficits. 1
- Recurrent sinusitis (≥3 episodes per year) requiring evaluation for underlying allergic rhinitis, immunodeficiency, or anatomic abnormalities. 1, 4
Common Pitfalls to Avoid
Do not obtain routine imaging (X-ray or CT) for uncomplicated ABRS; up to 87% of viral upper respiratory infections show sinus abnormalities on imaging, leading to unnecessary interventions. 1
Fluoroquinolones should not be used as first-line therapy in patients without documented β-lactam allergy to limit resistance development. 1
Ensure adequate treatment duration (≥5 days for adults, ≥10 days for children) to prevent relapse. 1
Gastrointestinal adverse effects with amoxicillin-clavulanate are common: diarrhea occurs in 40–43% of patients, with severe diarrhea in 7–8%. 1